Society of interventional radiology position statement on chemoembolization of hepatic malignancies

Journal of Vascular and Interventional Radiology

Volumn 17, Issue 2, 2006, Pages 217-223

  Brown, Daniel B ^a   Geschwind, Jean Francois H ^b   Soulen, Michael C ^c   Millward, Steven F ^e   Sacks, David ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d READING HOSPITAL AND MEDICAL CENTER   (United States)

^e Peterborough Regional Health Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; COLLAGEN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IODINATED POPPYSEED OIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; POLYVINYL ALCOHOL;

BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CHEMOEMBOLIZATION; CHOROID MELANOMA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG FATALITY; FEVER; HUMAN; INTERVENTIONAL RADIOLOGY; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER INFARCTION; LIVER TRANSPLANTATION; MEDICAL SOCIETY; METASTASIS; NAUSEA; NEUROENDOCRINE TUMOR; PAIN; PREVALENCE; PRIORITY JOURNAL; REVIEW; SARCOMA; SCORING SYSTEM; UNITED STATES; VOMITING; ARTICLE; CONTROLLED CLINICAL TRIAL; LIVER TUMOR; PALLIATIVE THERAPY; PATHOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; STANDARD; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; PALLIATIVE CARE; RADIOLOGY, INTERVENTIONAL; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 33746866389     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000196277.76812.A3     Document Type: Article

References (66)

1. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35S:72-78.
2. Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90:1562-1569.
3. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
4. Nakamura H, Hashimoto T, Oi H, et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989; 170:783-786.
5. Sasaki Y, Imaoka S, Kasugai H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987; 60:1194-1203.
6. Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer 1990; 66:1897-1903.
7. Egawa H, Maki A, Mori K, et al. Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats. J Surg Oncol 1990; 44:109-114.
8. Daniels JR, Sternlicht M, Daniels AM. Collagen chemoembolization: pharmacokinetics and tissue tolerance of cis-diamminedichloroplatinum(II) in porcine liver and rabbit kidney. Cancer Res 1988; 48:2446-2450.
9. Kruskal JB, Hlatky L, Hahnfeldt P, et al. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993; 4:741-747.
10. Ramsey DE, Kernagis LY, Soulen MC, et al. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13(suppl):S211-S221.
11. Li X, Feng GS, Zheng CS, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10:2878-2882.
12. Liao X, Yi J, Li X, et al. Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization. J Huazhong Univ Sci Technol Med Sci 2003; 23:280-282.
13. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224:47-54.
14. Kanematsu T, Furui J, Yanaga K, et al. A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000. Surgery 2002; 131:153-158.
15. Yanaga K. Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol 2004; 39:919-926.
16. Island ER, Pomposelli J, Pomfret EA, et al. Twenty-year experience with liver transplantation for hepatocellular carcinoma. Arch Surg 2005; 140:353-358.
17. Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2005; 128:1752-1764.
18. Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer 1988; 62:479-483.
19. Lee HS, Kim KM, Yoon JH, et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 2002; 20:4459-4465.
20. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37:429-442.
21. Solomon B, Soulen MC, Baum RA, et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 1999; 10:793-798.
22. Brown DB, Fundakowski CE, Lisker-Melman M. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2004; 15:1209-1218.
23. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31:133-141.
24. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256-1261.
25. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11:181-184.
26. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27:1578-1583.
27. Geschwind JF, Ramsey DE, Choti MA, et al. Chemoembolization of hepatocellular carcinoma: results of a meta-analysis. Am J Clin Oncol 2003; 26:344-349.
28. Trevisani F, De Notariis S, Rossi C, . Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol 2001; 32:383-389.
29. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171.
30. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739.
31. Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma: a 4-year study of 127 French patients. Cancer 1994; 74:16-24.
32. Barone M, Ettorre GC, Ladisa R, et al. Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. Hepatogastroenterology 2003; 50:183-187.
33. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91-96.
34. Fisher RA, Maluf D, Cotterell AH, et al. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 2004; 18:502-512.
35. Duszak R. Vascular occlusion: can we push radiofrequency ablation into new size frontiers? Radiology 2004; 231:291-292.
36. Yamakado K, Nakatsuka A, Ohmori S, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol 2002; 13:1225-1232.
37. Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000; 217:119-126.
38. Maluccio M, Covey AM, Gandhi R, et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol 2005; 16:955-961.
39. Bramhall SR, Gur U, Coldham C, et al. Liver resection for colorectal metastases. Ann R Coll Surg Engl 2003; 85:334-339.
40. Chafai N, Chan CL, Bokey EL, et al. What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer? Colorectal Dis 2005; 7:176-181.
41. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
42. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351.
43. Abramson RG, Rosen MP, Perry LJ, et al. Cost-effectiveness of hepatic arterial chemoembolization for colorectal liver metastases refractory to systemic chemotherapy. Radiology 2000; 216:485-491.
44. Lang EK, Brown CL. Colorectal metastases to the liver: selective chemoembolization. Radiology 1993; 189:417-422.
45. Sanz-Altamira PM, Spence LD, Huberman MS, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum 1997; 40:770-775.
46. Tellez C, Benson AB, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82:1250-1259.
47. Soulen MC. Chemoembolization of hepatic malignancies. Semin Intervent Radiol 1997; 14:305-311.
48. Salman HS, Cynamon J, Jagust M, et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2002; 2:173-179.
49. Vogl TJ, Mack MG, Balzer JO, et al. Liver metastases: neoadjuvant down-sizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology 2003; 229:457-464.
50. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993; 72:2219-2223.
51. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98:383-389.
52. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665-1670.
53. Mavligit GM, Charnsangavej C, Carrasco CH, et al. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988; 260:974-976.
54. Stokes K, Stuart K, Clouse M. Hepatic arterial chemoembolization for metastatic endocrine tumors. J Vasc Interv Radiol 1993; 4:341-345.
55. Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993; 189:541-547.
56. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 1999; 10:397-403.
57. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9:261-267.
58. Mavligit GM, Zukwiski AA, Ellis LM, et al. Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer 1995; 75:2083-2088.
59. Rajan DK, Soulen MC, Clark TWI, et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-c, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 2001; 12:187-193.
60. Burger I, Hong K, Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005; 16:353-361.
61. Giroux MF, Baum RA, Soulen MC. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol 2004; 15:289-291.
62. Mavligit GM, Estrov Z, Ayala A. Carcinoma of the stomach metastatic to the liver that progressed after hepatic arterial infusion of cisplatin plus 5-floxuridine, and then dramatically regressed after chemoembolization based on positive chromogranin staining. Am J Clin Oncol 1999; 22:320-322.
63. Andras C, Szucs Farkas Z, Csiki Z, et al. Clinical evaluation of local lipiodol chemoembolization therapy in primary and secondary hepatic tumors. Orv Hetil 2000; 141:1773-1777.
64. Caturelli E, Siena DA, Fusilli S, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology 2000; 215:123-128.
65. Kim W, Clark TWI, Baum RA, et al. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12:965-968.
66. Sakamoto I, Aso N, Nagaoki K, et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 1998; 18:605-619.